Dec 17 (Reuters) - Marker Therapeutics Inc MRKR.O:
MARKER THERAPEUTICS AWARDED $9.5 MILLION GRANT FROM THE CANCER PREVENTION & RESEARCH INSTITUTE OF TEXAS (CPRIT) TO SUPPORT THE INVESTIGATION OF MT-601 IN PATIENTS WITH PANCREATIC CANCER
MARKER THERAPEUTICS: PLANS TO INVESTIGATE ITS POTENTIAL APPLICATION BEYOND LYMPHOMA IN PATIENTS WITH SOLID TUMORS
MARKER THERAPEUTICS INC: ANTICIPATES CLINICAL PROGRAM INITIATION IN 2025
Source text: ID:nGNX24rf9p
Further company coverage: MRKR.O